Published in Vaccine Weekly, July 19th, 2006
"Although DNA-based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumor antigens are weak and fail to generate a vigorous immune response in tumor-bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune-activating genes to the tumor antigen sequence," noted scientists in Spain and Denmark.
"In this work, we converted a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.